Improved vaccine protects against nine types of HPV
Scientists have developed an improved vaccine commonly associated with cervical cancer...
List view / Grid view
Scientists have developed an improved vaccine commonly associated with cervical cancer...
A patient trial for KAF156, a next-generation antimalarial compound with the potential to treat drug-resistant strains of the malaria parasite has been launched...
Duke researchers used a bivalent virus from chicken cells that packaged twice as much protein as a monovalent virus, and vaccinated mice with either the bivalent or monovalent vaccine
Small skin patches with dissolvable microneedles were safe and well-tolerated, generated robust immunity against influenza, could be self-administered by study participants and were strongly preferred over shots.
12 May 2017 | By Niamh Marriott, Junior Editor
St. Jude Children’s Research Hospital and the Serum Institute of India will develop & commercialise a vaccine against the respiratory syncytial virus (RSV).
11 May 2017 | By Niamh Marriott, Junior Editor
EMA's report focuses on key achievements in the areas of medicine evaluation, support to R&D of new and innovative treatments and safety monitoring...
29 March 2017 | By Niamh Marriott, Junior Editor
We caught up with the CEO & CSO of Panacea for the latest on vaccine immunotherapies - "As a scientist, as long as you are observant and persistent, you may come up with breakthrough discoveries"
Commercial biomanufacturing dates to thousands of years and the first biological engine, the yeast, continues to be beneficial...
3 January 2017 | By Niamh Louise Marriott, Digital Editor
Sanofi and its vaccines business unit Sanofi Pasteur will end their vaccine joint-venture with MSD (known as Merck in the US and Canada) - SPMSD...
27 September 2016 | By Niamh Louise Marriott, Digital Content Producer
In July, Sanofi revealed the development agreement with the Walter Reed Army Institute of Research on the co-development of a Zika vaccine candidate...
15 August 2016 | By Sanofi
Results of the study affirm the vaccine's consistent efficacy in reducing dengue in two-thirds of the study participants, aged 9 and older. It also documents the ability of the vaccine to prevent 8 out of 10 hospitalisations and up to 93% of severe dengue cases in this age group during…
6 July 2016 | By Victoria White, Digital Content Producer
Scientists have developed a cost-effective vaccine cooler which preserves vaccines for 35 days using just 30 litres of ice and without needing electricity...
5 April 2016 | By Victoria White
Dengvaxia vaccinations of one million students from 6,000 public schools in the Philippines are to begin this year...
4 February 2016 | By Victoria White, European Pharmaceutical Review
The Zika virus has taken hold in South America. Its possible link to microcephaly in newborn babies and neurological conditions has led the World Health Organization to declare a Public Health Emergency of International Concern. Here we discuss the virus, countermeasures and the race for a vaccine.
Dengvaxia was shown to reduce dengue due to all four serotypes in two-thirds of the participants in clinical trials and prevent 8 out of 10 hospitalisations due to dengue and up to 93% of severe dengue cases...